In some cases, including breast cancer and CRC, the changes in expression of CLDN1 in tumors were shown to be associated with aggressive forms of diseases, larger tumor size, vascular invasion, higher pathological tumor stage, high metastatic lymph node ratio, and worse overall survival (OS) and progression-free survival (PFS) [61,62]. Here, CLDN1 is linked to breast carcinoma.